ClinicalTrials.gg
RecruitingNCT06143969USAT IH-PEUpdated Apr 16, 2026

Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism

An observational study in Pulmonary Embolism, sponsored by Niguarda Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Niguarda Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Pulmonary Embolism with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Pulmonary Embolism · Italy.

Planned enrollment
28th of 28
180 · median 623
Started
2022
with 2 others
Observational
28 of 57
6 open now
Registered
53rd of 57
by date

Among the 57 studies in Pulmonary Embolism with a site in Italy, this one is the 28th largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2022, is one of 28 observational ones, and was the 53rd registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

6 of the 57 studies in Pulmonary Embolism with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Pulmonary Embolism with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this retrospective and prospective multicenter study is to evaluate the incidence of pulmonary hypertension (PH) within 6 months from ultrasound-assisted, Catheter-directed Thrombolysis for acute intermediate- high-risk Pulmonary Embolism

Read the detailed description

Acute pulmonary embolism (PE) is a potentially life-threatening disease spanning a wide spectrum of clinical outcomes. PE is the third most common cardiovascular disorder in Europe and USA and causes an estimated 150,000 to 200,000 deaths.

In the latest 2019 European Society of Cardiology (ESC) Guidelines patients diagnosed with PE are stratified into different risk groups according to clinical history, hemodynamic status, cardiac biomarkers and imaging assessment of right ventricular (RV) function.

Traditionally, reperfusion therapy with systemic thrombolysis is the treatment of choice in high-risk PE, defined by sustained systemic arterial hypotension, cardiogenic shock, or the need for cardiopulmonary resuscitation.

In the setting of intermediate-risk PE,characterized by the absence of hemodynamic instability but elevated cardiac biomarkers or RV disfunction at imaging, the ESC guidelines recognize two sub-categories: intermediate-high if both signs are identified or intermediate-low, if only one of them is present.Approximately one quarter of hemodynamically stable patients with PE are at intermediate-risk, with mortality rates ranging from 3% to 15% if imaging or biomarker evidence of RV dilatation or dysfunction is present.4,5 In this subset of patients the optimal treatment strategy is still an object of debate.

A combination of ultrasound- based fragmentation of the thrombus and catheter-directed thrombolysis, requiring a reduced dose of the thrombolytic agent, has been developed. This localized therapy is currently recommended by the ESC guidelines (class IIa, LOE C) for patients with high-risk PE and contraindications for systemic thrombolysis or intermediate-high-risk PE and hemodynamic deterioration on anticoagulation treatment.

The investigators propose an observational cohort study aimed at assessing the impact on short and long-term outcome of ultrasound-assisted, catheter-directed thrombolysis using EKOSTM in a real-word population of subjects with acute intermediate-high risk PE treated in multiple Italian centers.

03

Conditions studied

  • Pulmonary Embolism

Browse trials for

Keywords

  • pulmonary embolism
  • intermediate high-risk
  • Ultrasound-assisted
  • Catheter-directed Thrombolysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients hospitalized with intermediate high-risk pulmonary embolism

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted with acute intermediate-high risk PE, defined according to ESC guidelines
  • Symptoms onset within previous 14 days associated or not with deep venous thrombosis
  • Confirmation of the PE by contrast-enhanced computed tomography of the chest with embolus located in at least one main or proximal lower lobe pulmonary artery
  • Echocardiographic parameters of RV disfunction
  • Patients with high-risk PE or hemodynamic deterioration on anticoagulation, who have absolute (high bleeding risk) to systemic thrombolysis and symptoms onset during the last 14 days. Patients with surgery-related embolic complications are also included (within 48 hours).

Exclusion criteria

Exclusion Criteria

  • Age \< 18 years old
  • Patients unable to give
  • Pregnancy
  • Patients received fibrinolytic drugs in the preceding 4 days
  • Bleeding diathesis
  • Known bleeding disorder
  • Low count (\< 100.000/uL
  • Gastrointestinal bleeding in the preceding 3 month
  • Any ongoing known presence of malignant neoplasia months
  • Advanced chronic kidney disease (defined as 11.000/uL)
  • Gastrointestinal bleeding in the preceding 3 month
  • Any ongoing known presence of malignant neoplasia at admission with survival rate \< 6
  • Advanced chronic kidney disease (defined as \< 30 ml/min or on dialysis)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • EkoSonicTM Endovascular System (EKOSTM, Boston Scientific)

    Patients hospitalized with acute intermediate-high risk PE treated with ultrasound-assisted, catheter-directed thrombolysis using EKOSTM.

    Procedure: ultrasound-assisted, catheter-directed thrombolysis

Interventions

  • Procedureultrasound-assisted, catheter-directed thrombolysis

    After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.

    Also known as: EkoSonicTM Endovascular System (EKOSTM, Boston Scientific)

06

What researchers measure

Primary outcomes

  1. development of pulmonary hypertension

    number of cases

    Time frame: 6 months from treatment

Secondary outcomes

  1. changes of echocardiographic parameters

    * tricuspid annular plane excursion (TAPSE) (mm) * right ventricle/left ventricle ratio (RV/LV) ratio (decimal) * acceleration time (ACT) time (seconds) * fractional area change (FAC) * S' TDI RV (cm/sec) * pulmonary artery systolic pressure (PAPs) (mmHg) * tricuspid regurgitant velocity (TRV) (m/s)

    Time frame: 24 hours after the treatment and at 3-6 months follow-up

  2. death

    death during hospital stay (number of events)

    Time frame: within 6 months from treatment

  3. death

    death from any cause (cancer, sepsis, respiratory failure, other) number of events

    Time frame: within 6 months from treatment

  4. PE

    PE recurrence (number of events)

    Time frame: within 6 months from treatment

  5. Major bleeding within 6 months from treatment (Bleeding Academic Research Consortium-major bleedings defined as BARC 3-5 events; clinically relevant non major bleedings defined as BARC 2 event) (number of events)

    Bleeding Academic Research Consortium-major bleedings defined as BARC 3-5 events; clinically relevant non major bleedings defined as BARC 2 event (number of events)

    Time frame: within 6 months from treatment

  6. stroke

    number of events

    Time frame: within 6 months from treatment

  7. Re-hospitalization

    Re-hospitalization (number of events)

    Time frame: within 6 months from treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's planned 48 months is close to that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Nov 22, 2023
StartActual
Nov 28, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06143969
Lead sponsor
Niguarda Hospital
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 28, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Alice Sacco, MD
Contact
alice.sacco@ospedaleniguarda.it
0039026444 ext. 2565
Dario Brunelli, PhD
Contact
dario.brunelli@ospedaleniguarda.it
0039026444 ext. 6516

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion